ABSTRACT
INTRODUCTION
Ulcerative colitis (UC) is an immune-mediated inflammatory reaction of the intestinal mucosa, characterized by relapse and remission. Immune modulation with thiopurines (TP) is a widely used mode of treatment for inflammatory bowel disease (IBD). Although they are considered the drug of choice for steroid refractory or resistant patients, thiopurines have also shown efficacy in the induction and maintenance of remission in adult populations (1, 2) . Recent reports support the potency of thiopurines in the management of IBD (3, 4) . Once the remission is established, maintenance is elicited in two-thirds of patients at 1 year with thiopurines (5). Hyams et al. (6) has recently reported that TP alone establish remission up to 1 year in half of the children with UC. A large cohort of pediatric patients has documented efficacy in up to 50% of patients at 1 year, and a more recent report documented that long-term use of TP is well tolerated and relatively safe (6) .
The knowledge about the effectiveness, failure, and toxicity of long-term treatment with TP is limited. Adverse drug reactions are divided into two categories: idiosyncratic and dose dependent. An adverse reaction probably falls in the first category if it occurs a few weeks after the treatment commences in an immunologically mediated and unpredictable manner. Reactions include fatigue, dizziness, vomiting, diarrhea, fever, myalgia, arthralgia, rash, and hypotension (7), and they can also rarely include renal insufficiency, pneumonia (8) (9) (10) , and pancreatitis, an increase of liver enzymes, hepatitis, cholestatic jaundice, or hepatic veno-occlusive disease (11 TP is widely used among children and adolescents, there are no data concerning its long-term use over the course of 1 year within the pediatric population. Therefore, in the current study, we aimed to evaluate the efficacy, tolerability, adverse reactions, and safety of a long-term TP use in a cohort of children with UC.
MATERIALS AND METHODS
Data were collected retrospectively from the records of patients diagnosed with UC at our center between 2005 and 2016. The diagnosis of UC was based on radiological, conventional clinical, histological, and endoscopic evaluation. Only patients with moderate and severe ulcerative colitis were included in the study. All UC patients at this intercept were analyzed at the 4-week, 6-week, and 3-month intervals after the occurrence of remission to determine patient characteristics, thiopurine properties, and its efficacy and toxicity. The determination of remission, relapse, and steroid refractoriness/dependency was guided by the European Crohn's and Colitis Organisation consensus. The pediatric UC activity index had not been used until 2009 in our unit; therefore, scoring was excluded from the evaluation due to missing cases.
Thiopurine was prescribed by a pediatric gastroenterologist after the parents' consent was obtained, according to the local protocol. Azathioprine (AZA) (Immuran, GlaxoSmithKline, Middlesex, UK) was started at a dose of 2-2.5 mg/kg/d at the time of diagnosis or as the maintenance therapy during evaluation for a dose reduction of steroids at 4, 8, or 12 weeks. An active infection, bone marrow suppression, and pre-existing liver disease were accepted as contraindications for TP use.
Forty-eight UC cases were evaluated, and sequential numbers were calculated for those who continued to use AZA at 3, 12, 24, 36, 48, and 60 months. Clinical remission was defined by a decrease in UC symptoms, including a reduction in stool frequency, reduced rectal blood loss, and weight gain. The AZA treatment was withdrawn due to the unresponsiveness and/or development of adverse events (AEs).
The occurrence of new symptoms or signs, the deterioration of pre-existing conditions, and any laboratory abnormalities occurring after the initiation of AZA were considered to be AEs. A complete blood count and renal and liver function tests were recorded at follow-up visits, and symptoms associated with laboratory/imaging reports were registered. Hepatotoxicity, gastrointestinal complaints, myelotoxicity, pancreatitis, fever, malaise, arthralgia, and a variety of other conditions were classified as AEs. Hepatotoxicity was defined as the acceleration of liver enzymes twice or more than the upper normal limit. Nausea and vomiting were accepted as adverse gastrointestinal events. Leukocyte counts lower than 3,500/mm 3 , thrombocyte levels under 150,000/mm 3 , and/or hemoglobin levels below the age reference limit were defined as myelotoxicity. Clinical pancreatitis was defined based on the classical clinical symptoms associated with elevated acute phase reactants and amylase, and/or lipase levels over two times greater than the upper normal limit. A peripheral or mucosal temperature over 38.5°C and 39°C, respectively, was accepted as fever. An abdominal ultrasound was performed on patients who had miscellaneous complaints during the TP follow-up, and parenchymal changes in the liver and spleen were recorded. The study was prepared in accordance with the Helsinki Declaration.
Statistical analysis
The data are presented descriptively. The Student's t-test and one-way analysis of variance were used where appropriate. A Kaplan-Meier analysis was used to designate TP continuation, and the influence of co-treatments was researched by a Cox-regression analysis. All the statistical analyses were performed using the MedCalcx Software (Ostend, Belgium, https: medcalc.org, 2013) version 12.7.7.
RESULTS
Forty-eight patients with UC who received AZA were included in the study. The mean age was 12.4±3.5 years, and the group included 33 females (68.7%) and 15 males (31.25%). The patient characteristics are shown in Table  1 . The follow-up periods of the patients were a minimum of 1 year, a maximum of 10 years, and a median of 6 years. Azathioprine was started at a median of 1 month (0-12 months) and prescribed as part of remission induction in 5 cases (10.4%, 2 left-sided, 3 pancolitis), while it was started after for maintenance (n=43). The response to remission induction was obtained in 40 (93.7%) patients, and calcineurin inhibitors were started in 5 cases. During the follow-up, infliximab was initiated in 8 cases, and only 1 patient underwent colectomy because of recurrent relapses in the follow-up. The relapse rate of patients on AZA appeared in 14 (29.1%) cases at a median time of 13 months (5-26) ( Table 1 ).
The mean duration of AZA treatment was 24 months (5-63). In 34 (85%) of the 40 children, AZA was well tolerated until the last visit. After the first year, 68.5% of the patients did not have to use steroids or another rescue therapy, along with 58.3% of patients who received AZA for maintenance therapy after the second year. Due to adverse effects, 6 patients could not tolerate treatment. Table 2 summarizes the characteristics of 6 patients. Dose reduction (1 mg/kg/d) resulted in the normalization of neutropenia in 2 cases, and AZA was switched to AZA/ MP in 2 remaining cases who had gastrointestinal complaints. Mercaptopurine was well tolerated in Case 3, but neutropenia and gastrointestinal disturbance were sustained on MP in Case 4. Concomitant aminosalicylate (n: 24) or biologic agent application (n: 4) was not related to AZA discontinuation (p=0.5).
Laboratory findings at the baseline and last visit are shown in Table 3 . No significant difference was observed under AZA treatment. The mean duration of AZA treatment was 24 months (5-63).
DISCUSSION
In the treatment of UC, thiopurines are widely used; however, control data are limited (6, 12) . Clinical supervision and patient follow-up are necessary to determine the AEs that occur during thiopurine therapy. Regular monitoring of laboratory indices, such as peripheral blood count and pancreatic and liver function tests, can thus be utilized (13, 14) . Normal follow-ups on laboratory indicators can also be monitored. There is no consensus on monitoring thiopurine activity and the toxicity determinants of the active thiopurine metabolite, and their use is not fully suggested or accepted, depending largely on the local practitioners' and clinicians' choices (15) . Thiopurine metabolite monitoring is not available at our center, so laboratory purine markers are absent in the current analyses.
Controlled trials have shown that thiopurine is effective in steroid tapering and maintaining remission in patients with UC (11). Many meta-analyzes have also shown the efficacy of thiopurine for the induction and maintenance of remission in patients with UC (3, 16). Hyams et al. reported 103 patients at a 2-year follow-up after thiopurine initiation, with 51 (50%) having CS-free (corticosteroid-free) inactive disease and 13 (13%) having CS-free inactive disease without rescue therapy. Forty-six of these patients were evaluated at 5 years, and 7% of them showed CS-free mild disease without rescue therapy (6).
In the Lev-Tzion's study, at 4 months, 35 (64%) of the 59 evaluable patients were in clinical remission, at 12 months, and 3153% of the 59 patients were clinical remission (12). In our study, the clinical remission rate without a steroid therapy was 68.5% at 12 months and 58.3% at 2 years.
It is potentially helpful to use thiopurine to prevent the AEs of steroids in patients with UC taking steroids for a long time. According to the study by Hyams et al., after the first year, 49% of patients did not need to use steroids, while after the second year, 50% of patients did not need to use steroids (6) . According to our study, these rates were 68.5% and 58.3%, respectively. The AEs of thiopurine may lead to treatment cessation. In the study by Satoshi et al., 28.8% of patients were observed to experience AEs, and the treatment was discontinued in 6 patients. These AEs included EBV (Epstein Barr Virus) in 1 patient, vomiting in 1 patient, pancreatitis in 1 patient, leukopenia in 1 patient, and liver disfunction in 2 patients (17).
Chaparro et al. (18) reported findings from a comprehensive and prospective cohort study in Spain, where 67% of 1,026 patients discontinued thiopurine therapy due to AEs, such as nausea, arthralgia, alopecia, abdominal pain, liver and pancreatic toxicity, leucopenia, myelotoxicity, and infection. Thiopurine methyltransferase or thiopurine S-methyltransferase (TPMT) should be measured before the thiopurine therapy is initiated, because severe pancytopenia has been reported in patients with TPMT deficiency (18) . It is important to note that the TPMT levels do not predict the majority of myelotoxicity cases, and ongoing hematologic surveillance is very important (19) . Reports indicate that 50% to 75% of thiopurine-induced leukopenia cases occur in patients with normal TPMT levels (20, 21) . However, we could not measure the TMTP level in our hospital. In our study, an AE was observed in 6 (15%) patients. There were no deaths or malignancies in the patient population during the study period. The AEs in our study included nausea in 2 patients, vomiting, diarrhea, and neutropenia in 2 patients, leukopenia in 1 patient, and skin rash in 1 patient. For these AEs, the medicine doses in 2 patients were decreased, while the AEs of 2 patients resolved spontaneously. In addition, because the AEs continued in 2 patients, the treatment was changed to mercaptopurine.
The present study has several limitations, being conducted on a single-center patient population and having a retrospective design. As a result, long-term observational data show that thiopurine therapy in patients with UC is beneficial in maintaining remission. The patients with UC can be sustained in remission by thiopurine for a long-term surveillance. The security border of thiopurine treatment is related to therapeutic effect, toxicity, and intolerance. A regular follow-up is obligatory to ensure this effect.
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